| Literature DB >> 10745068 |
E A Schaff1, S L Fielding, S H Eisinger, L S Stadalius, L Fuller.
Abstract
The aim of this study was to compare the effectiveness, side effects, and acceptability of one-third the standard dose of mifepristone, i.e., 200 mg, and vaginal misoprostol 800 microg to induce abortion in subjects < or =56 days pregnant with subjects 57-63 days pregnant. A prospective multicenter trial enrolled healthy women > or =18 years, < or =63 days pregnant, and wanting an abortion. Women received mifepristone 200 mg orally, followed by misoprostol 800 microg vaginally, and returned 1-4 days later for ultrasound evaluation. A second dose of misoprostol was administered, if necessary. Surgical intervention was indicated for continuing pregnancy, excessive bleeding, or persistent products of conception 5 weeks later. Of 1137 subjects, 829 were in the < or =56 days pregnant group and 308 in the 57-63 days pregnant group. In all, 34 subjects had surgical intervention and 16 were lost to follow-up. Complete medical abortions occurred in 97% of subjects < or =56 days pregnant and 96% in the 57-63 days pregnant group. In all, 88% of subjects in the < or =56 days pregnant and 92% in the 57-63 days pregnant group bled within 4 h of using vaginal misoprostol. Comparing subjects < or =56 days pregnant with 57-63 days pregnant, there was less diarrhea (20% vs 29%, p = 0.002) and vomiting (33% vs 44%, p = 0.001), although side effects were acceptable to 82% of subjects in both groups. One subject in the < or =56 day group required a transfusion for delayed excessive bleeding. Although bleeding (p = 0.01) and pain (p = 0.02) were less acceptable in the 57-63 day group, 91% of subjects in both groups reported that the overall procedure was acceptable. In summary, low-dose mifepristone 200 mg and home administration of vaginal misoprostol 800 microg at 48 h were highly effective and acceptable to women < or =63 days pregnant, thereby expanding the number of women who can access a medical abortion.Entities:
Keywords: Abortion, Drug Induced; Abortion, Induced; Americas; Biology; Clinical Research; Comparative Studies; Developed Countries; Endocrine System; Family Planning; Fertility Control, Postconception; Hormone Antagonists; Hormones; Misoprostol; North America; Northern America; Physiology; Prospective Studies; Prostaglandins; Prostaglandins, Synthetic; Research Methodology; Research Report; Ru-486; Studies; United States
Mesh：
Substances：
Year: 2000 PMID： 10745068 DOI： 10.1016/s0010-7824(99)00119-5
Source DB: PubMed Journal: Contraception ISSN： 0010-7824 Impact factor: 3.375